Related Experiment Video
Updated: Jul 16, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
FB1, an E2A fusion partner in childhood leukemia, interacts with U19/EAF2 and inhibits its transcriptional activity
Feng Jiang1, Junkui Ai, Wuhan Xiao
1Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Background:
U19/EAF2 is a potential tumor suppressor exhibiting frequent down-regulation and allelic loss in advanced human prostate cancer specimens. U19/EAF2 has also been identified as ELL-associated factor 2 (EAF2) based on its binding to ELL, a fusion partner of MLL in acute myeloid leukemia. U19/EAF2 is a putative transcription factor with a transactivation domain and capability of sequence-specific DNA binding.
Methods:
Yeast-two-hybrid-screening was used to identify U19/EAF2-binding partners. Co-immunoprecipitation and mammalian 1-hybrid assay were used to characterize a U19/EAF2-binding partner.
Results:
FB1, an E2A fusion partner in childhood leukemia, was identified as a binding-partner of U19/EAF2. FB1 also binds to EAF1, the only homologue of U19/EAF2. FB1 also interacts and co-localizes with ELL in the nucleus. Interestingly, FB1 inhibited the transcriptional activity of U19/EAF2 but not EAF1.
Conclusions:
FB1 is an important binding partner and a functional regulator of U19/EAF2, EAF1, and/or ELL.
Insights
FB1 protein interacts with U19/EAF2, a potential tumor suppressor in prostate cancer. FB1 regulates the transcriptional activity of U19/EAF2, suggesting a role in cancer development.
Area of Science:
- Molecular Biology
- Cancer Research
- Transcriptional Regulation
Background:
- U19/EAF2, also known as ELL-associated factor 2 (EAF2), is a potential tumor suppressor frequently downregulated in advanced prostate cancer.
- EAF2 is a transcription factor capable of DNA binding and possesses a transactivation domain.
- EAF2 binds to ELL, a fusion partner in MLL-associated acute myeloid leukemia.
Purpose of the Study:
- To identify binding partners of U19/EAF2.
- To characterize the interaction between U19/EAF2 and its binding partners.
- To investigate the functional consequences of these interactions on transcriptional activity.
Main Methods:
- Yeast-two-hybrid screening to identify U19/EAF2 binding partners.
- Co-immunoprecipitation assays to confirm protein interactions.
- Mammalian one-hybrid assays to assess transcriptional activity.
Main Results:
- FB1, an E2A fusion partner in childhood leukemia, was identified as a U19/EAF2 binding partner.
- FB1 also binds to EAF1, the homolog of U19/EAF2, and interacts/co-localizes with ELL in the nucleus.
- FB1 inhibited the transcriptional activity of U19/EAF2 but not EAF1.
Conclusions:
- FB1 is a significant binding partner of U19/EAF2.
- FB1 acts as a functional regulator of U19/EAF2, EAF1, and/or ELL.
- These findings highlight a novel regulatory mechanism involving FB1 in transcriptional processes relevant to cancer.
Related Concept Videos
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Abnormal Proliferation
Mitogens and the Cell Cycle
General Transcription Factors
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

